相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Hypomagnesemia and clinical benefits of anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer: a systematic review and meta-analysis
Meng-Chiao Hsieh et al.
SCIENTIFIC REPORTS (2018)
HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models
Dongsheng Wang et al.
CLINICAL CANCER RESEARCH (2017)
Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash
Jesper Grau Eriksen et al.
SUPPORTIVE CARE IN CANCER (2017)
Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: A systematic review
Pierluigi Bonomo et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Reported outcomes of children with newly diagnosed high-grade gliomas treated with nimotuzumab and irinotecan
Nongnuch Sirachainan et al.
CHILDS NERVOUS SYSTEM (2017)
The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes
Brian M. Necela et al.
CLINICAL AND TRANSLATIONAL MEDICINE (2017)
Premedication and Chemotherapy Agents do not Impair Imgatuzumab (GA201)-Mediated Antibody-Dependent Cellular Cytotoxicity and Combination Therapies Enhance Efficacy
Valeria Gonzalez-Nicolini et al.
CLINICAL CANCER RESEARCH (2016)
Antibody-drug conjugates as drug carrier systems for bioactive agents
Muhammad Sajid Hamid Akash et al.
INTERNATIONAL JOURNAL OF POLYMERIC MATERIALS AND POLYMERIC BIOMATERIALS (2016)
Antibody-drug conjugates as drug carrier systems for bioactive agents
Muhammad Sajid Hamid Akash et al.
INTERNATIONAL JOURNAL OF POLYMERIC MATERIALS AND POLYMERIC BIOMATERIALS (2016)
Combination pertuzumab, trastuzumab, and taxane for metastatic breast cancer after first progression: a single institution's experience
Bao D. Dao et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2016)
Understanding EGFR Signaling in Breast Cancer and Breast Cancer Stem Cells: Overexpression and Therapeutic Implications
Ibrahim O Alanazi et al.
Asian Pacific Journal of Cancer Prevention (2016)
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18
Silvia Carvalho et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors
Satoshi Yoshiba et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2016)
A novel fully-human cytolytic fusion protein based on granzyme B shows in vitro cytotoxicity and ex vivo binding to solid tumors overexpressing the epidermal growth factor receptor
Judith Niesen et al.
CANCER LETTERS (2016)
The First-in-class Anti-EGFR Antibody Mixture Sym004 Overcomes Cetuximab Resistance Mediated by EGFR Extracellular Domain Mutations in Colorectal Cancer
Francisco J. Sanchez-Martin et al.
CLINICAL CANCER RESEARCH (2016)
New developments for antibody-drug conjugate-based therapeutic approaches
Bart E. C. G. de Goeij et al.
CURRENT OPINION IN IMMUNOLOGY (2016)
Nanobodies as therapeutics: big opportunities for small antibodies
Sophie Steeland et al.
DRUG DISCOVERY TODAY (2016)
Pertuzumab for the treatment of breast cancer: a safety review
Jennifer Gao et al.
EXPERT OPINION ON DRUG SAFETY (2016)
Immunotherapy for pancreatic cancer
Elias Kotteas et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2016)
A combination of two antibodies recognizing non-overlapping epitopes of HER2 induces kinase activity-dependent internalization of HER2
Monika Szymanska et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2016)
Recombinant targeted toxin based on HER2-specific DARPin possesses a strong selective cytotoxic effect in vitro and a potent antitumor activity in vivo
Evgeniya Sokolova et al.
JOURNAL OF CONTROLLED RELEASE (2016)
The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity
Gabor Toth et al.
MABS (2016)
Adaptive responses to antibody based therapy
Tamara S. Rodems et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2016)
Mutations of KRAS/NRAS/BRAF predict cetuximab resistance in metastatic colorectal cancer patients
Hung-Chih Hsu et al.
ONCOTARGET (2016)
Bispecific Antibody Conjugated Manganese-Based Magnetic Engineered Iron Oxide for Imaging of HER2/neu- and EGFR-Expressing Tumors
Shou-Cheng Wu et al.
THERANOSTICS (2016)
Immunotoxin Therapies for the Treatment of Epidermal Growth Factor Receptor-Dependent Cancers
Nathan Simon et al.
TOXINS (2016)
Antibody-drug conjugates for cancer therapy: The technological and regulatory challenges of developing drug-biologic hybrids
Gregory S. Hamilton
BIOLOGICALS (2015)
Acquired resistance to anti-EGFR mAb ICR62 in cancer cells is accompanied by an increased EGFR expression, HER-2/HER-3 signalling and sensitivity to pan HER blockers
Said A. Khelwatty et al.
BRITISH JOURNAL OF CANCER (2015)
A proof of concept trial of the anti-EGFR antibody mixture Sym004 in patients with squamous cell carcinoma of the head and neck
J. -P. Machiels et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Preclinical pharmacokinetics, pharmacodynamics, and efficacy of RG7116: a novel humanized, glycoengineered anti-HER3 antibody
Georgina Meneses-Lorente et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
被撤回的出版物: Silencing EGFR/HER3 signaling with a novel anti-EGFR domain II/IV antibody(Retracted article.See vol.401, pg.81, 2017)
Shi Hu et al.
CANCER LETTERS (2015)
Preclinical efficacy of Sym004, novel anti-EGFR antibody, in esophageal squamous cell carcinoma cell lines
Shota Fukuoka et al.
CANCER RESEARCH (2015)
Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors
Dejan Juric et al.
CLINICAL CANCER RESEARCH (2015)
Pan-HER, an Antibody Mixture Simultaneously Targeting EGFR, HER2, and HER3, Effectively Overcomes Tumor Heterogeneity and Plasticity
Helle J. Jacobsen et al.
CLINICAL CANCER RESEARCH (2015)
The relevance of ADCC for EGFR targeting: A review of the literature and a clinically-applicable method of assessment in patients
Martino Monteverde et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2015)
Bispecific antibodies
Roland E. Kontermann et al.
DRUG DISCOVERY TODAY (2015)
Necitumumab for non-small cell lung cancer
Laurent Greillier et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2015)
Prospective phase II trial of nimotuzumab in combination with radiotherapy and concurrent capecitabine in locally advanced rectal cancer
Ting Jin et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2015)
Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities
Judith Niesen et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous non-small-cell lung cancer (SQUIRE): an open-label, randomised, controlled phase 3 trial
Nick Thatcher et al.
LANCET ONCOLOGY (2015)
Multifunctional receptor-targeting antibodies for cancer therapy
Yanni Zhu et al.
LANCET ONCOLOGY (2015)
Mechanisms of action of therapeutic antibodies for cancer
J. M. Redman et al.
MOLECULAR IMMUNOLOGY (2015)
Fully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer
Yan Zhou et al.
MOLECULAR MEDICINE REPORTS (2015)
Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN)
Katharine A. R. Price et al.
ORAL ONCOLOGY (2015)
Current ADC Linker Chemistry
Nareshkumar Jain et al.
PHARMACEUTICAL RESEARCH (2015)
Targeting HER family in HER2-positive metastatic breast cancer: potential biomarkers and novel targeted therapies
Ines de Paula Costa Monteiro et al.
PHARMACOGENOMICS (2015)
Improved biological activity of a single chain antibody fragment against human epidermal growth factor receptor 2 (HER2) expressed in the periplasm of Escherichia coli
Vajihe Akbari et al.
PROTEIN EXPRESSION AND PURIFICATION (2015)
Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
Maicol Mancini et al.
SCIENCE SIGNALING (2015)
High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers
Hee Jin Lee et al.
VIRCHOWS ARCHIV (2015)
Safety and Activity of the First-in-Class Sym004 Anti-EGFR Antibody Mixture in Patients with Refractory Colorectal Cancer
Rodrigo Dienstmann et al.
CANCER DISCOVERY (2015)
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the THERAPY phase 1-2 trial
Eric Assenat et al.
ONCOTARGET (2015)
Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance
Markus Morkel et al.
ONCOTARGET (2015)
Small Sized EGFR1 and HER2 Specific Bifunctional Antibody for Targeted Cancer Therapy
Li Ding et al.
THERANOSTICS (2015)
Combining three antibodies nullifies feedback-mediated resistance to erlotinib in lung cancer
Maicol Mancini et al.
SCIENCE SIGNALING (2015)
Role of ErbB Receptors in Cancer Cell Migration and Invasion
Aline Appert-Collin et al.
FRONTIERS IN PHARMACOLOGY (2015)
Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab
Fan Zhang et al.
ONCOIMMUNOLOGY (2015)
Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors
Joanne A. Hammill et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2015)
Clinical Translation and Validation of a Predictive Biomarker for Patritumab, an Anti-human Epidermal Growth Factor Receptor 3 (HER3) Monoclonal Antibody, in Patients With Advanced Non-small Cell Lung Cancer
Jeanne Mendell et al.
EBIOMEDICINE (2015)
Trastuzumab emtansine: mechanisms of action and drug resistance
Mark Barok et al.
BREAST CANCER RESEARCH (2014)
Role of HER3 expression and PTEN loss in patients with HER2-overexpressing metastatic breast cancer (MBC) who received taxane plus trastuzumab treatment
Y. H. Park et al.
BRITISH JOURNAL OF CANCER (2014)
ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics
Carlos L. Arteaga et al.
CANCER CELL (2014)
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck
Vassiliki Saloura et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
IMGN289, an EGFR-targeting antibody-drug conjugate, is effective against tumor cells that are resistant to EGFR tyrosine kinase inhibitors
Yulius Y. Setiady et al.
CANCER RESEARCH (2014)
Molecular Pathways: HER3 Targeted Therapy
Kinisha Gala et al.
CLINICAL CANCER RESEARCH (2014)
Chimeric Rat/Human HER2 Efficiently Circumvents HER2 Tolerance in Cancer Patients
Sergio Occhipinti et al.
CLINICAL CANCER RESEARCH (2014)
Translational genomics and head and neck cancer: toward precision medicine
S. Razzouk
CLINICAL GENETICS (2014)
Open-label, multicentre expansion cohort to evaluate imgatuzumab in pre-treated patients with KRAS-mutant advanced colorectal carcinoma
Jean-Pierre Delord et al.
EUROPEAN JOURNAL OF CANCER (2014)
Primary and acquired resistance to EGFR-targeted therapies in colorectal cancer: impact on future treatment strategies
Simonetta M. Leto et al.
JOURNAL OF MOLECULAR MEDICINE-JMM (2014)
Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy
Josep Lluis Parra-Palau et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2014)
Targeting of erbB3 receptor to overcome resistance in cancer treatment
Jian Ma et al.
MOLECULAR CANCER (2014)
MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Network Adaptations That Limit Activity of IGF-IR Inhibitors
Jonathan B. Fitzgerald et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Generation of a Canine Anti-EGFR (ErbB-1) Antibody for Passive Immunotherapy in Dog Cancer Patients
Josef Singer et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells
D. Raina et al.
ONCOGENE (2014)
HER3, serious partner in crime Therapeutic approaches and potential biomarkers for effect of HER3-targeting
Arjan Kol et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Postulated Mechanisms of Resistance of B-Cell Non-Hodgkin Lymphoma to Rituximab Treatment Regimens: Strategies to Overcome Resistance
Benjamin Bonavida
SEMINARS IN ONCOLOGY (2014)
Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer
Dan Su et al.
TUMOR BIOLOGY (2014)
Targeting of preexisting and induced breast cancer stem cells with trastuzumab and trastuzumab emtansine (T-DM1)
J. Diessner et al.
CELL DEATH & DISEASE (2014)
Dual Inhibition of EGFR with Afatinib and Cetuximab in Kinase Inhibitor-Resistant EGFR-Mutant Lung Cancer with and without T790M Mutations
Yelena Y. Janjigian et al.
CANCER DISCOVERY (2014)
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
Joan T. Garrett et al.
CANCER RESEARCH (2013)
The anti-EGFR ADC, IMGN289 displays favorable pharmacokinetic properties
Jose F. Ponte et al.
CANCER RESEARCH (2013)
Development of a novel antibody-maytansinoid conjugate, IMGN289, for the treatment of EGFR-expressing solid tumors.
Yulius Y. Setiady et al.
CANCER RESEARCH (2013)
IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway.
Thomas D. Chittenden et al.
CANCER RESEARCH (2013)
Preclinical evaluation of IMGN289, an anti-EGFR antibody-maytansinoid conjugate for the treatment of squamous cell carcinoma of the head and neck
Jose F. Ponte et al.
CANCER RESEARCH (2013)
RG7116, a Therapeutic Antibody That Binds the Inactive HER3 Receptor and Is Optimized for Immune Effector Activation
Christian Mirschberger et al.
CANCER RESEARCH (2013)
An Antibody That Locks HER3 in the Inactive Conformation Inhibits Tumor Growth Driven by HER2 or Neuregulin
Andrew P. Garner et al.
CANCER RESEARCH (2013)
CDK inhibitor p57Kip2 is downregulated by Akt during HER2-mediated tumorigenicity
Ruiying Zhao et al.
CELL CYCLE (2013)
Dual Blockade of HER2 in HER2-Overexpressing Tumor Cells Does Not Completely Eliminate HER3 Function
Joan T. Garrett et al.
CLINICAL CANCER RESEARCH (2013)
Molecular Pathways: Involvement of Immune Pathways in the Therapeutic Response and Outcome in Breast Cancer
Fabrice Andre et al.
CLINICAL CANCER RESEARCH (2013)
Increased TGF-α as a Mechanism of Acquired Resistance to the Anti-EGFR Inhibitor Cetuximab through EGFR-MET Interaction and Activation of MET Signaling in Colon Cancer Cells
Teresa Troiani et al.
CLINICAL CANCER RESEARCH (2013)
A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer
J. T. Hartmann et al.
INVESTIGATIONAL NEW DRUGS (2013)
Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas
Tanja Trarbach et al.
INVESTIGATIONAL NEW DRUGS (2013)
Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006
Mothaffar F. Rimawi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Inhibition of pancreatic carcinoma by homo- and heterocombinations of antibodies against EGF-receptor and its kin HER2/ErbB-2
Ruth Maron et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer
Anna Emde et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2012)
Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma
Ana Markovic et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2012)
Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
Jeremy S. Logue et al.
GENES & DEVELOPMENT (2012)
Treatment of HER2-positive breast cancer: current status and future perspectives
Carlos L. Arteaga et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2012)
Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer
Sunil Verma et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
The promise of anti-ErbB3 monoclonals as new cancer therapeutics
Luigi Aurisicchio et al.
ONCOTARGET (2012)
The ERBB network: at last, cancer therapy meets systems biology
Yosef Yarden et al.
NATURE REVIEWS CANCER (2012)
Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
Pasi A. Jaenne et al.
CLINICAL CANCER RESEARCH (2011)
Monoclonal antibodies against EGFR in non-small cell lung cancer
Robert Pirker et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2011)
A biparatopic anti-EGFR nanobody efficiently inhibits solid tumour growth
Rob C. Roovers et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Phase I Pharmacokinetic and Pharmacodynamic Dose-Escalation Study of RG7160 (GA201), the First Glycoengineered Monoclonal Antibody Against the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors
Luis G. Paz-Ares et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial
Jean-Pascal Machiels et al.
LANCET ONCOLOGY (2011)
Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways
Siyuan Zhang et al.
NATURE MEDICINE (2011)
Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties
Jeffrey L. Nordstrom et al.
BREAST CANCER RESEARCH (2011)
PTEN, PIK3CA, p-AKT, and p-p70S6K Status Association with Trastuzumab Response and Survival in Patients with HER2-Positive Metastatic Breast Cancer
Francisco J. Esteva et al.
AMERICAN JOURNAL OF PATHOLOGY (2010)
Pemetrexed with or without Matuzumab as Second-Line Treatment for Patients with Stage IIIB/IV Non-small Cell Lung Cancer
Joan H. Schiller et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
Yung-Jue Bang et al.
LANCET (2010)
New Antibody Conjugates in Cancer Therapy
Serengulam V. Govindan et al.
THESCIENTIFICWORLDJOURNAL (2010)
Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells
Panagiotis Karagiannis et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2009)
Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment
Jaume Capdevila et al.
CANCER TREATMENT REVIEWS (2009)
A pan-HER approach for cancer therapy: background, current status and future development
Zhongdong Huang et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Cetuximab and Other Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in the Treatment of Non-Small Cell Lung Cancer
Cesare Gridelli et al.
ONCOLOGIST (2009)
Current situation of panitumumab, matuzumab, nimotuzumab and zalutumumab
Fernando Rivera et al.
ACTA ONCOLOGICA (2008)
Developments in epidermal growth factor receptor-targeting therapy for solid tumors: Focus on matuzumab (EMD 72000)
Joan H. Schiller
CANCER INVESTIGATION (2008)
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer
Rafael G. Amado et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice
Clifford A. Hudis
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer
Eric Van Cutsem et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
A phase I study of the humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody EMD 72000 (matuzumab) in combination with paclitaxel in patients with EGFR-positive advanced non-small-cell lung cancer (NSCLC)
C. Kollmannsberger et al.
ANNALS OF ONCOLOGY (2006)
The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells
QB She et al.
CANCER CELL (2005)
Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
D Cunningham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
分享论文
